Ionis Pharmaceuticals (IONS) Stock
Biotech company developing targeted medicines for rare diseases. Here's the price, business snapshot, and what's worth knowing about Ionis Pharmaceuticals in October 2026.
Ionis Pharmaceuticals (IONS) is a US‑based biotechnology company specialised in antisense oligonucleotide (ASO) therapeutics — short strands of RNA designed to modulate gene expression. With a market capitalisation of about $11.42 billion, Ionis operates a platform-driven model: it advances a pipeline across neurology, cardiometabolic and rare diseases while partnering with larger pharma firms for development, regulatory and commercialisation support. Revenue typically comes from milestone payments, licensing fees and royalties rather than steady product sales, which can make financials lumpy. The company’s science-driven approach offers the potential for targeted medicines where conventional drugs struggle, but the path from early research to approved therapy is lengthy and uncertain. Investors should expect clinical trial binary events, regulatory dependency and periodic volatility. This profile is for educational purposes only and is not investment advice; prospective investors should consider their risk tolerance and seek personalised advice before investing.
Ionis Pharmaceuticals (IONS) Stock Forecast
Analyst price target, next 12 months
$70.43
+61.8% vs today's $43.54
Price range over the last 12 months
Close to its 12-month low
Analysts covering Ionis Pharmaceuticals have a consensus 12-month target of $70.43, above the current price of $43.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ionis Pharmaceuticals' stock with a target price of $70.43, indicating strong potential for growth.
Financial Health
Ionis Pharmaceuticals is showing strong revenue and cash flow, with excellent profit margins.
Dividend
Ionis Pharmaceuticals has a projected dividend yield of 0.14%, which is below average for dividend-paying stocks. If you invested $1000 you would be paid $1.40 a year in dividends (based on the last 12 months).
Discover More Opportunities
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
Why You’ll Want to Watch This Stock
Antisense Platform
A platform approach can create multiple development candidates from one technology, which investors may find compelling though outcomes vary and timelines are long.
Partner Deals Matter
Collaborations with larger pharma provide funding and commercial reach, but revenues often depend on milestone timing and partner strategy.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions can significantly move the share price, but those events also carry binary downside risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
